This article is more than 5 years old. Information may no longer be current.

DePuy Synthes enters representative agreement with LifeNet Health

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

DePuy Synthes and DePuy Synthes Biomaterials, divisions of DePuy Orthopaedics Inc., have entered into an exclusive worldwide representative agreement for the marketing and promotion of a new cellular allograft product developed by LifeNet Health.

According to a company press release, the representative agreement marks the entry of DePuy Synthes Spine, in collaboration with DePuy Synthes Biomaterials, into cellular allografts for spinal fusion and bolsters the group’s portfolio of biomaterial solutions for the treatment of spinal and orthopedic pathologies.

“Our clinical, sales and marketing teams are energized by this new collaboration that will offer clinicians a new technology for treating spine patients,” Max Reinhardt, worldwide president of DePuy Synthes Spine, stated in the release. “We are excited to collaborate with LifeNet Health and our colleagues in DePuy Synthes Biomaterials to enhance our product offering with biomaterials that complement and augment our spine portfolio.”